SAN DIEGO, Nov. 10, 2017 /PRNewswire/ -- Tocagen Inc.
(Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy
company, today announced that Marty
Duvall, chief executive officer, will present at the
following upcoming investor conferences:
- Stifel Nicolaus Healthcare Conference, Tuesday, November 14, 11:45 a.m. ET in New
York City
- Evercore ISI Biopharma Catalyst/Deep Dive Conference,
Wednesday, November 29, 2:00 p.m. ET in Boston
The live audio webcast from the conferences and subsequent
replay may be accessed by visiting Tocagen's website. The
webcasts will be available shortly after conclusion of the
presentation and archived on the company's website for 90 days
following the presentation.
About Tocagen
Tocagen is a clinical-stage, cancer-selective gene therapy
company developing first-in-class, broadly applicable product
candidates designed to activate a patient's immune system against
their own cancer. Tocagen is developing its lead investigational
product candidate, Toca 511 & Toca FC, initially for the
treatment of recurrent high grade glioma (HGG), a disease with
significant unmet medical need. The U.S. Food and Drug
Administration (FDA) has granted Toca 511 & Toca FC
Breakthrough Therapy Designation for the treatment of recurrent HGG
and the European Medicines Agency (EMA) has granted Toca 511 PRIME
(PRIority MEdicines) designation for the treatment of HGG.
Forward-Looking Statements
Statements contained in
this press release regarding matters that are not historical facts
are "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Because such statements
are subject to risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking
statements. Such statements include, but are not limited to,
statements regarding our business plans and objectives, timing and
success of our clinical trials and planned clinical trials, timing
of results from our clinical trials and our plans regarding
selection of additional product candidates. Risks that contribute
to the uncertain nature of the forward-looking statements include:
the success, cost and timing of our product candidate development
activities and planned clinical trials; our ability to execute on
our strategy; regulatory developments in the United States and foreign countries; and
our estimates regarding expenses, future revenue and capital
requirements. These and other risks and uncertainties are described
more fully under the caption "Risk Factors" and elsewhere in
Tocagen's filings and reports with the United States Securities and
Exchange Commission. All forward-looking statements contained in
this press release speak only as of the date on which they were
made. Tocagen undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made.
View original content with
multimedia:http://www.prnewswire.com/news-releases/tocagen-to-present-at-two-investor-conferences-in-november-300553684.html
SOURCE Tocagen Inc.